Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 20;27(1):40.
doi: 10.1007/s12017-025-08865-x.

Improvement of Parkinson's Disease Symptoms by Butylphthalide Through Modulation of Microglial Activation

Xue Wang  1 , Huimin Shi  1 , Zibin Wei  1 , Ping Liu  1 , Shujuan Tian  2 , Xueqin Song  3   4   5
Affiliations

Improvement of Parkinson's Disease Symptoms by Butylphthalide Through Modulation of Microglial Activation

Xue Wang et al. Neuromolecular Med. .

Abstract

Microglia-mediated neuroinflammation plays an important role in the pathogenesis of Parkinson's disease (PD). Studies have shown that butylphthalide (3-n-butylphthalide or NBP) can play an anti-inflammatory role in other diseases by regulating the activation of microglia. This study investigates the neuroprotective and anti-inflammatory effects of NBP in a mouse model of Parkinson's disease (PD) induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The primary aim was to determine whether NBP can improve symptoms of PD by modulating microglial activation and to explore the underlying mechanisms involved. Motor function (assessed via Open Field and Pole Climbing tests), dopaminergic neuronal loss, and activation of different microglial subtypes were assessed in control, MPTP-treated, and NBP + MPTP-treated mice. A p38 phosphorylation inhibitor + MPTP group was also established to investigate potential mechanisms of NBP action. Mice treated with NBP exhibited significantly improved motor function and reduced dopaminergic neuronal loss compared to MPTP-treated mice. In PD mice, pro-inflammatory factor expression was elevated, anti-inflammatory factor expression was reduced, and the expression of arginase-1 (arg-1), a marker for M2 microglia, was decreased. NBP treatment resulted in reduced levels of pro-inflammatory factors, increased levels of anti-inflammatory factors, and elevated arg-1 expression. Additionally, inhibition of p38 phosphorylation further decreased pro-inflammatory factor expression while increasing both anti-inflammatory factor levels and arg-1 expression. The findings indicate that NBP regulates neuroinflammation and improves symptoms of PD by promoting the transformation of microglia to the M2 phenotype, likely mediated through the p38 phosphorylation pathway.

Keywords: Butylphthalide; Dopaminergic neuronal loss; Microglial activation; Neuroinflammation; Parkinson’s disease.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Ethical Approval: The ethical approval for the animal experiments obtained from the Institutional Animal Care and Use Committee.

Similar articles

See all similar articles

References

    1. Björkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., & Magnusson, A. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. The Journal of Experimental Medicine, 205(8), 1869–1877. - DOI - PubMed - PMC
    1. Chauhan, P., & Sheng, W. S. (2021). Differential cytokine-induced responses of polarized microglia. Brain Sciences, 11(11), 1482. - DOI - PubMed - PMC
    1. Dal Bianco, A., Bradl, M., Frischer, J., Kutzelnigg, A., Jellinger, K., & Lassmann, H. (2008). Multiple sclerosis and Alzheimer’s disease. Annals of Neurology, 63(2), 174–183. - DOI
    1. Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Björkqvist, M., Petersén, Å., Jackson, G. S., Isaacs, J. D., Kristiansen, M., Bates, G. P., & Leavitt, B. R. (2007). Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates. Journal of Proteome Research, 6(7), 2833–2840. - DOI - PubMed
    1. Doorn, K. J., Moors, T., Drukarch, B., van de Berg, W., Lucassen, P. J., & van Dam, A. M. (2014). Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients. Acta Neuropathologica Communications, 2, 90. - PubMed - PMC

MeSH terms

LinkOut - more resources